Photo from wikipedia
Key Points Question Is use of targeted disease-modifying antirheumatic drugs associated with risk of Alzheimer disease and related dementia (ADRD)? Findings In this cohort study including 22 569 propensity score–matched patient… Click to show full abstract
Key Points Question Is use of targeted disease-modifying antirheumatic drugs associated with risk of Alzheimer disease and related dementia (ADRD)? Findings In this cohort study including 22 569 propensity score–matched patient pairs, initiation of inhibitors of Janus-kinase, interleukin-6, or tumor necrosis factor was not associated with reduced risk of ADRD compared with initiation of abatacept, a T-cell activation inhibitor. Meaning These results do not support advancing targeted disease-modifying antirheumatic drugs as disease modifying candidates for ADRD.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!